BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the San Antonio Breast Cancer Symposium (SABCS), Dec 9-12, 2025, in San Antonio, Texas. Both posters feature BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction.
Details: a Late-Breaking Pre-clinical poster (Abstract 3568, Presentation PS2-12-06) on Dec 10, 5:00–6:30 p.m. CT by Kerstin Sinkevicius, PhD, reports tumor growth inhibition alone and combined with fulvestrant or ribociclib without inducing hyperglycemia. A Trials-in-Progress poster (Abstract 203, Presentation PS5-07-06) on Dec 12, 12:30–2:00 p.m. CT by Andreas Varkaris, MD, PhD, outlines the phase 1a/1b BREAKER-101 study of BBO-10203 in advanced solid tumors.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) ha annunciato due poster al San Antonio Breast Cancer Symposium (SABCS), dal 9 al 12 dicembre 2025, a San Antonio, Texas. Entrambi i poster presentano BBO-10203, descritto come un candidato di prima classe, oralmente bio-disponibile, che interrompe in modo selettivo l'interazione RAS:PI3Kα.
Dettagli: un poster preclinico in ritardo (Late-Breaking Pre-clinical poster) (Abstract 3568, Presentazione PS2-12-06) il 10 dicembre, dalle 17:00 alle 18:30 CT, a cura di Kerstin Sinkevicius, PhD, riporta l'inibizione della crescita tumorale sia da solo sia in combinazione con fulvestrant o ribociclib senza indurre iperglicemia. Un poster di Trials-in-Progress (Abstract 203, Presentazione PS5-07-06) il 12 dicembre, dalle 12:30 alle 14:00 CT, a cura di Andreas Varkaris, MD, PhD, descrive lo studio BREAKER-101 di fase 1a/1b di BBO-10203 in tumori solidi avanzati.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) anunció dos presentaciones en póster en el San Antonio Breast Cancer Symposium (SABCS), del 9 al 12 de diciembre de 2025, en San Antonio, Texas. Ambos pósteres presentan BBO-10203, descrito como un candidato de primera clase, disponible por vía oral, que rompe selectivamente la interacción RAS:PI3Kα.
Detalles: un póster preclínico de última hora (Late-Breaking Pre-clinical poster) (Abstract 3568, Presentación PS2-12-06) el 10 de diciembre, de 5:00 a 6:30 p.m. CT, por Kerstin Sinkevicius, PhD, reporta inhibición del crecimiento tumoral tanto solo como en combinación con fulvestrant o ribociclib sin inducir hiperglucemia. Un póster de Trials-in-Progress (Abstract 203, Presentación PS5-07-06) el 12 de diciembre, de 12:30 a 2:00 p.m. CT, por Andreas Varkaris, MD, PhD, describe el estudio BREAKER-101 de fase 1a/1b de BBO-10203 en tumores sólidos avanzados.
BridgeBio Oncology Therapeutics (나스닥: BBOT)가 샌안토니오 유방암 심포지엄(SABCS)에서 2025년 12월 9-12일 텍사스주 샌안토니오에서 포스터 2편을 발표했다고 발표했다. 두 포스터 모두 BBO-10203를 특징으로 하며, 이는 RAS:PI3Kα 상호 작용을 선택적으로 경구로 사용할 수 있는 일류의 브레이커로 설명된다.
세부 사항: 12월 10일 17:00~18:30 CT에 열리는 Late-Breaking Pre-clinical 포스터(Abstract 3568, 발표 PS2-12-06)에서 Kerstin Sinkevicius 박사에 의해 보고된 내용은 단독으로 또는 fulvestrant나 ribociclib과의 병용 시에도 종양 성장 억제가 나타나고 고혈당증을 유발하지 않는다는 것이다. 12월 12일 12:30~14:00 CT에 열리는 Trials-in-Progress 포스터(Abstract 203, 발표 PS5-07-06)에서 Andreas Varkaris 박사(MD, PhD)가 주도하는 BREAKER-101 1a/1b 연구가 진행 중인 고형 종양에서의 BBO-10203를 설명한다.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) a annoncé deux présentations poster au San Antonio Breast Cancer Symposium (SABCS), du 9 au 12 décembre 2025, à San Antonio, Texas. Les deux posters présentent BBO-10203, décrit comme un candidat de première classe, oralement biodisponible, et qui rompt sélectivement l’interaction RAS:PI3Kα.
Détails : un poster préclinique d’actualité tardive (Late-Breaking Pre-clinical poster) (Abstract 3568, Présentation PS2-12-06) le 10 décembre, 17:00–18:30 CT, par Kerstin Sinkevicius, PhD, rapporte une inhibition de la croissance tumorale seule et en combinaison avec fulvestrant ou ribociclib sans induire d’hyperglycémie. Un poster Trials-in-Progress (Abstract 203, Présentation PS5-07-06) le 12 décembre, 12:30–14:00 CT, par Andreas Varkaris, MD, PhD, décrit l’étude Breaker-101 de phase 1a/1b de BBO-10203 dans des tumeurs solides avancées.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) gab zwei Poster-Präsentationen auf dem San Antonio Breast Cancer Symposium (SABCS) vom 9. bis 12. Dezember 2025 in San Antonio, Texas, bekannt gegeben. Beide Poster zeigen BBO-10203, beschrieben als first-in-class, oral bioverfügbarer, selektiver Bruch der RAS:PI3Kα-Interaktion.
Details: Ein Late-Breaking Pre-clinical Poster (Abstract 3568, Präsentation PS2-12-06) am 10. Dezember von 17:00 bis 18:30 Uhr CT, von Kerstin Sinkevicius, PhD, berichtet über Tumorwachstumshemmung sowohl alleine als auch in Kombination mit Fulvestrant oder Ribociclib, ohne Hyperglykämie auszulösen. Ein Trials-in-Progress Poster (Abstract 203, Präsentation PS5-07-06) am 12. Dezember von 12:30 bis 14:00 Uhr CT, von Andreas Varkaris, MD, PhD, skizziert die Phase-1a/1b-Studie BREAKER-101 von BBO-10203 bei fortgeschrittenen soliden Tumoren.
BridgeBio Oncology Therapeutics (ناسداك: BBOT) أعلنت عن عرضين بارزين في الملصقين في مؤتمر SABCS لسرطان الثدي في سان أنطونيو (SABCS)، من 9 إلى 12 ديسمبر 2025، في سان أنطونيو، تكساس. كلا الملصقين يعرضان BBO-10203، الموصوف كمكون رائد في فئته، قابل للاستخدام عن طريق الفم، وباحث عن كسر تفاعل RAS:PI3Kα بشكل انتقائي.
التفاصيل: ملصق ما قبل السريري متأخر النشر (Late-Breaking Pre-clinical poster) (Abstract 3568, العرض PS2-12-06) في 10 ديسمبر، من الساعة 5:00 إلى 6:30 مساءً بتوقيت CT، بواسطة Kerstin Sinkevicius، دكتوراه، ي/report عن تثبيط نمو الورم منفردًا وبالاشتراك مع fulvestrant أو ribociclib دون التسبب في ارتفاع سكر الدم. ملصق Trials-in-Progress (Abstract 203, العرض PS5-07-06) في 12 ديسمبر من 12:30 إلى 2:00 مساءً CT، بواسطة Andreas Varkaris، دكتور في الطب و دكتور في الفلسفة، يوضح دراسة BREAKER-101 للمرحلة 1a/1b لـ BBO-10203 في أورام صلبة متقدمة.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here.
Late Breaking Pre-clinical Poster Details:
- Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
- Presentation Number: PS2-12-06
- Abstract Number: 3568
- Session Date/Time: Wednesday, December 10, from 5:00 p.m. - 6:30 p.m. CT
- Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
Trials in Progress Poster Details:
- Title: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
- Presentation Number: PS5-07-06
- Abstract Number: 203
- Session Date/Time: Friday, December 12, from 12:30 p.m. – 2:00 p.m. CT
- Presenter: Andreas Varkaris, MD, PhD, Attending Physician and Investigator, Massachusetts General Hospital
About BBO-10203
BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. This novel mechanism of action makes BBO-10203 agnostic to the mutational status of either RAS or PI3Kα providing the potential to treat tumors driven by KRAS or PI3Kα mutations, the two most mutated oncogenes in human cancer. BBO-10203 is being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
When will BBOT present BBO-10203 posters at SABCS 2025?
What is the focus of the BBOT late‑breaking pre‑clinical poster at SABCS (BBOT, Dec 10, 2025)?
What does the BREAKER-101 trial poster (BBOT, Dec 12, 2025) describe?
Who are the BBOT presenters for the SABCS 2025 posters?
Where can I find the BBOT SABCS 2025 abstracts and poster numbers?
